US › Healthcare

Cocrystal Pharma Inc (COCP)

US · Healthcare · Biotechnology

$1.140.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$105,000

Net profit

$-3.2M

EPS

$-0.23

EPS estimate

$-0.17

Net margin

-3,013.3%

EPS came in at -0.23 against a street estimate of -0.17 — a miss of 35.3%.

Key statistics

Market cap

$22.0M

Forward P/E

0.0

P/B

21.13

Book value

$0.08

EPS (TTM)

$-0.73

52-week high

$2.03

52-week low

$0.76

50-day MA

$1.05

200-day MA

$1.09

Beta

1.48

Analyst view

Analysts rate Cocrystal Pharma Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $9.00.

Shareholding

Insiders

65.71%

Institutions

5.77%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.25%
Two Sigma Investments LLC	0.91%
Renaissance Technologies Corp	0.64%
Geode Capital Management, LLC	0.47%
BlackRock Inc	0.38%
Citadel Advisors Llc	0.23%
XTX Topco Ltd	0.19%
Neuberger Berman Group LLC	0.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cocrystal Pharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.